Is the c-Cbl proto-oncogene involved in chronic lymphocytic leukemia?

Annals of the New York Academy of Sciences

Volumn 1107, Issue , 2007, Pages 193-205

  Mankaï, Amani ^a,b,c   Eveillard, Jean Richard ^a   Buhé, Virginie ^a   Le Ster, Karine ^a   Loisel, Séverine ^a   Ghedira, Ibtissem ^b   Youinou, Pierre ^a   Berthou, Christian ^a   Bordron, Anne ^a  

^a BREST UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c Pharmacy Faculty   (Tunisia)

Author keywords

c Cbl; CLL; PLC 2; Survival pathways; ZAP 70

Indexed keywords

CBL PROTEIN; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE ZAP 70; CD5 ANTIGEN; MESSENGER RNA; PHOSPHOLIPASE C GAMMA; PHOSPHOTYROSINE;

ADULT; AGED; B LYMPHOCYTE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; ONCOGENE; PHOSPHORYLATION; ARTICLE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD5; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PHOSPHOLIPASE C GAMMA; PHOSPHOTYROSINE; PROTO-ONCOGENE PROTEINS C-CBL; RNA, MESSENGER; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 34648847082     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1381.021     Document Type: Conference Paper

References (25)

1. ANDREEFF, M., Z. DARZYNKIEWICZ, T.K. SHARPLESS, et al. 1980. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 55: 282-293.
2. BINET, J.L., A. AUQUIER, G. DIGHIERO, et al. 1981. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198-206.
3. CRESPO, M., F. BOSCH, N. VILLAMOR, et al. 2003. ZAP-70 expression as a surrogate for immunoglobulin-variable- region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348: 1764-1775.
4. HAYAT, A., D. O'BRIEN, P. O'ROURKE, et al. 2006. CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk. Lymphoma 47: 2371-2379.
5. ZANOTTI, R., A. AMBROSETTI, M. LESTANI, et al. 2007. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia 21: 102-109.
6. NEDELLEC, S., Y. RENAUDINEAU, A. BORDRON, et al. 2005. B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. J. Immunol. 174: 3749-3756.
7. CHEN, L., J. APGAR, L. HUYNH, et al. 2005. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 105: 2036-2041.
8. BARRAGAN, M., B. BELLOSILLO, C. CAMPAS, et al. 2002. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 99: 2969-2976.
9. YASUDA, T., A. MAEDA, M. KUROSAKI, et al. 2000. Cbl suppresses B cell receptor-mediated phospholipase C (PLC)-gamma2 activation by regulating B cell linker protein-PLC-gamma2 binding. J. Exp. Med. 191: 641-650.
10. DIKIC, I., I. SZYMKIEWICZ & P. SOUBEYRAN. 2003. Cbl signaling networks in the regulation of cell function. Cell. Mol. Life Sci. 60: 1805-1827.
11. DIKIC, I.& S. GIORDANO. 2003. Negative receptor signaling. Curr. Opin. Cell Biol. 15: 128-135.
12. BLAKE, T.J., K.G. HEATH & W.Y. LANGDON. 1993. The truncation that generated the v-cbl oncogene reveals an ability for nuclear transport, DNA binding and acute transformation. EMBO J. 12: 2017-2026.
13. OTA, Y. & L.E. SAMELSON. 1997. C-Cbl may function both as a negative regulator of tyrosine kinases and as a multi functional adaptor protein. Science 276: 418-420.
14. LANGDON, W.Y. 1995. The cbl oncogene: a novel substrate of protein tyrosine kinases. Aust. N. Z. J. Med. 25: 859-864.
15. LIVAK, K.J. & T.D. SCHMITTGEN. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
16. TAGUCHI, T., N. KIYOKAWA, H. TAKENOUCH, et al. 2004. Deficiency of BLNK hampers PLC-gamma2 phosphorylation and Ca2+ influx induced by the pre-B-cell receptor in human pre-B cells. Immunology 112: 575-582.
17. INGHAM, R.J., D.L. KREBS, S.M. BARBAZUK, et al. 1996. B cell antigen receptor signaling induces the formation of complexes containing the Crk adapter proteins. J. Biol. Chem. 271: 32306-32314.
18. NARAMURA, M., I.K. JANG, H. KOLE, et al. 2002. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat. Immunol. 3: 1192-1199.
19. KIM, S.Z., K.U. CHOW, N. KUKOC-Z IVOJNOV, et al. 2004. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leuk. Lymphoma 45: 2037-2045.
20. CUTRONA, G., M. COLOMBO, S. MATIS, et al. 2006. B lymphocytes in humans express ZAP-70 when activated in vivo. Eur. J. Immunol. 36: 558-569.
21. WANG, H.Y., Y. ALTMAN, D. FANG, et al. 2001. Cbl promotes ubiquitination of the T cell receptor zeta through an adaptor function of Zap-70. J. Biol. Chem. 276: 26004-26011.
22. LUPHER JR, M.L., Z. Songyang, S.E. Shoelson, et al. 1997. The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70. J. Biol. Chem. 272: 33140-33144.
23. ZHANG, Z., C. ELLY, A. ALTMAN, et al. 1999. Dual regulation of T cell receptor-mediated signaling by oncogenic Cbl mutant 70Z. J. Biol. Chem. 274: 4883-4889.
24. HUNTER, S., E.A. BURTON, S. C. WU, et al. 1999. Fyn associates with Cbl and phosphorylated tyrosine 731 in Cbl, a binding site for phosphatitdylinositol 3-kinase. J. Biol. Chem. 274: 2097-2106.
25. UENO, H., K. SASAKI, H. HONDA, et al. 1998. C-Cbl is tyrosine phosphorylated by interleukin-4 and enhances mitogenic and survival signals of interleukin-4 receptor by linking with the phosphatidylinositol 3-kinase pathway. Blood 91: 46-53.